Favrille CEO to Present at NewsMakers in the Biotech Industry Investment ...( Live Webcast from the Millennium Br...)

Live Webcast from the Millennium Broadway Hotel in New York on Thursday,

September 6th

SAN DIEGO, Aug. 27 /PRNewswire-FirstCall/ -- Favrille, Inc. (Nasdaq: FVRL), a biopharmaceutical company developing patient-specific, active immunotherapies for the treatment of cancer, today announced that John P. Longenecker, Ph.D., President and Chief Executive Officer, will present at the NewsMakers in the Biotech Industry investment conference at 9:00 a.m. Eastern time on Thursday, September 6, 2007. The conference, presented by BioCentury and Thomson, will be held at the Millennium Broadway Hotel in New York City.

(Logo: http://www.newscom.com/cgi-bin/prnh/20031013/LAM095LOGO)

Dr. Longenecker will provide an overview of Favrille and the clinical trials of its lead compound, FavId(R), which is currently in a pivotal Phase 3 clinical trial for the treatment of follicular B-cell non-Hodgkin's lymphoma (NHL). A live webcast of the presentation can be accessed at http://www.favrille.com. The replay will be available approximately one hour after the presentation and will be archived until October 6, 2007.

About Favrille, Inc.

Favrille, Inc. is a biopharmaceutical company focused on the development and commercialization of targeted immunotherapies for the treatment of cancer and other diseases of the immune system. The Company's lead product candidate, FavId, is based upon unique genetic information extracted from a patient's tumor. FavId is currently under investigation in a pivotal Phase 3 clinical trial for patients with follicular B-cell NHL and Phase 2 clinical trials in other B-cell NHL indications. The Company is developing additional applications based on its immunotherapy expertise and proprietary cost-effective manufacturing technology, including a second product candidat
'/>"/>